Bright Minds Biosciences Inc. (NASDAQ:DRUG – Free Report) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Bright Minds Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the company will post earnings of ($0.62) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($2.58) per share.
Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) last announced its quarterly earnings results on Monday, December 30th. The company reported ($0.12) earnings per share for the quarter.
Check Out Our Latest Report on DRUG
Bright Minds Biosciences Price Performance
Shares of NASDAQ DRUG opened at $32.28 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.31 and a quick ratio of 11.31. Bright Minds Biosciences has a 1-year low of $0.93 and a 1-year high of $79.02. The company has a market capitalization of $143.13 million, a price-to-earnings ratio of -64.56 and a beta of -6.52. The business has a 50-day moving average of $38.36 and a 200-day moving average of $21.08.
Bright Minds Biosciences Company Profile
Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.
Featured Articles
- Five stocks we like better than Bright Minds Biosciences
- Canadian Penny Stocks: Can They Make You Rich?
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Why is the Ex-Dividend Date Significant to Investors?
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Stock Average Calculator
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.